Another limitation is that reactivation of FBXW7 tumor suppressor functions, through gene editing or gene transfer therapy, is not easily feasible in vivo. However, the wide range of pro-oncogenic targets makes FBXW7 highly valuable for therapeutic targeting. This evidence concerns the gene FBXW7 and neoplasm.